Associated Papers
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
40259101 (PubMed )
Supplement: 41375_2025_2625_MOESM2_ESM.xlsx › Sheet5
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
36989067 (PubMed )
Supplement: BLOODA_ADV-2022-009564-mmc2.xlsx › SuppTable2
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Luque Paz D et al.
Hemasphere, 2023
37153874 (PubMed )
Supplement: hs9-7-e885-s001.xlsx › Supplemental_Table_S2
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N et al.
Leukemia, 2022
35922444 (PubMed )
Supplement: 41375_2022_1650_MOESM2_ESM.xlsx › NGS_dataset
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
35650444 (PubMed )
Supplement: 41586_2022_4785_MOESM12_ESM.xlsx › AML
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.
Yao WQ et al.
The Journal of Pathology, 2020
31859368 (PubMed )
Supplement: PATH-250-346-s006.xlsx › mutation__3_
Genetic basis of myelodysplastic syndromes.
Ogawa S
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 2020
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
Ma X et al.
Nature, 2018
29489755 (PubMed )
Supplement: NIHMS939556-supplement-Table_2-7.xlsx › TableS5
[IDH1/2 gene mutations in myelodysplastic syndromes].
Yoshida K et al.
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2012
Select a paper to view details